Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Acta Psychiatr Scand. 2003 May;107(5):344-50.

Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study.

Author information

  • 1Psychiatric Department O, Psychiatric Clinic, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. bsoeholm@dadlnet.uk



To evaluate the long-term effectiveness of the second generation antipsychotics, risperidone and olanzapine on hospitalization, clinical response, and adherence to therapy after switching from conventional antipsychotics or clozapine in a naturalistic setting of schizophrenic patients.


Data were registered for periods of identical duration before and after switching.


Fifty-seven patients were included. Mean study period was 3.1 +/- 0.2 years. Mean number of in-patient days after switching declined by 78% of the level before switching (P=0.0002). There was no significant differences in ratio responders/non-responders between the subgroups. The number of patients with extrapyramidal symptoms (EPS) was significantly reduced after switching. However, intolerable weight gain led to a lack of adherence to therapy in 18% of the olanzapine-treated patients.


Long-term treatment with the second generation antipsychotics, risperidone and olanzapine significantly improved the clinical outcome. However, weight gain may be a significant reason for discontinuation of treatment and reducing the long-term adherence to therapy.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk